- Home
- NXT vs ICLR Comparison
NXT vs ICLR Comparison
Compare NXT & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXT | ICLR |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.3B |
| IPO Year | 2023 | 1998 |
Fundamental Metrics
Financial Performance| Metric | NXT | ICLR |
|---|---|---|
| Price | $86.91 | $182.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 14 |
| Target Price | $91.80 | ★ $202.38 |
| AVG Volume (30 Days) | ★ 1.8M | 832.9K |
| Earning Date | 01-27-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 3.85 | ★ 7.47 |
| Revenue | $3,373,226,000.00 | ★ $8,102,602,000.00 |
| Revenue This Year | $17.53 | N/A |
| Revenue Next Year | $11.36 | $0.66 |
| P/E Ratio | ★ $22.59 | $24.48 |
| Revenue Growth | ★ 20.37 | N/A |
| 52 Week Low | $36.06 | $125.10 |
| 52 Week High | $112.74 | $228.29 |
Technical Indicators
Market Signals| Indicator | NXT | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 54.12 |
| Support Level | $89.01 | $180.48 |
| Resistance Level | $92.90 | $184.93 |
| Average True Range (ATR) | 4.24 | 5.11 |
| MACD | -0.04 | -0.33 |
| Stochastic Oscillator | 21.09 | 52.96 |
Price Performance
Historical ComparisonAbout NXT Nextracker Inc.
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.